NEW YORK, Nov. 2 – Variagenics recorded a drop in revenues and a widened net loss for the third quarter 2001 compared with the same period last year, the company said.

The Cambridge, Mass.-based pharmacogenomics company said revenues for the three months ended Sept. 30 fell to $600,000 from $800,000 one year earlier. Basic and diluted net loss, meanwhile, jumped to $6.6 million, or $0.28 per share, from $6.4 million, or $0.35 for the third quarter of 2000.

Still, the company remained optimistic about its outlook.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.